JP2005504522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504522A5 JP2005504522A5 JP2003507063A JP2003507063A JP2005504522A5 JP 2005504522 A5 JP2005504522 A5 JP 2005504522A5 JP 2003507063 A JP2003507063 A JP 2003507063A JP 2003507063 A JP2003507063 A JP 2003507063A JP 2005504522 A5 JP2005504522 A5 JP 2005504522A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- growth factor
- receptor
- antisense oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims 7
- 238000012230 antisense oligonucleotides Methods 0.000 claims 7
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 7
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 7
- 239000003102 growth factor Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000001246 colloidal dispersion Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000005934 immune activation Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/888,361 US20030064944A1 (en) | 2001-06-21 | 2001-06-21 | Antisense modulation of transforming growth factor beta receptor II expression |
| PCT/US2002/019665 WO2003000656A2 (en) | 2001-06-21 | 2002-06-19 | Antisense modulation of transforming growth factor beta receptor ii expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504522A JP2005504522A (ja) | 2005-02-17 |
| JP2005504522A5 true JP2005504522A5 (enExample) | 2006-01-12 |
Family
ID=25393053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003507063A Pending JP2005504522A (ja) | 2001-06-21 | 2002-06-19 | トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030064944A1 (enExample) |
| EP (1) | EP1406915A4 (enExample) |
| JP (1) | JP2005504522A (enExample) |
| AU (1) | AU2002316318A1 (enExample) |
| WO (1) | WO2003000656A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101543B2 (en) * | 2000-03-31 | 2006-09-05 | Novarx | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| SG145713A1 (en) * | 2003-08-13 | 2008-09-29 | Univ Illinois | SILENCING OF TGFss TYPE II RECEPTOR EXPRESSION BY SIRNA |
| CN1989244B (zh) * | 2004-02-09 | 2013-04-03 | 柏格丹由里 | 用于治疗cns病症的tgf-r信号传递抑制剂 |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| GB2440782A (en) * | 2006-08-04 | 2008-02-13 | Cesare Peschle | Uses and compositions comprising miRNAs |
| WO2008109546A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof |
| WO2009060122A2 (en) * | 2007-11-05 | 2009-05-14 | Baltic Technology Development, Ltd. | Use of oligonucleotides with modified bases as antiviral agents |
| WO2010013350A1 (ja) * | 2008-08-01 | 2010-02-04 | Ａｓｐｉｏｎ株式会社 | Ｓ／ｏ型経皮免疫剤 |
| CR20160554A (es) * | 2014-05-01 | 2017-03-07 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento |
| EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| US11028390B2 (en) * | 2017-07-10 | 2021-06-08 | Osaka University | Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof |
| CN111788216B (zh) * | 2017-12-18 | 2023-06-23 | 森正之 | 盐泡细胞形成控制作用剂和导入了该作用剂的植物体 |
| CN115812102B (zh) * | 2020-02-12 | 2025-07-04 | 广州安天圣施医药有限公司 | 反义寡核苷酸及其在治疗耳聋-甲状腺肿综合征中的应用 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008011A (en) * | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2001
- 2001-06-21 US US09/888,361 patent/US20030064944A1/en not_active Abandoned
-
2002
- 2002-06-19 EP EP02746611A patent/EP1406915A4/en not_active Withdrawn
- 2002-06-19 WO PCT/US2002/019665 patent/WO2003000656A2/en not_active Ceased
- 2002-06-19 JP JP2003507063A patent/JP2005504522A/ja active Pending
- 2002-06-19 AU AU2002316318A patent/AU2002316318A1/en not_active Abandoned
-
2003
- 2003-11-10 US US10/705,715 patent/US20040147472A1/en not_active Abandoned